Lyn is involved in CD24-induced ERK1/2 activation in colorectal cancer

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Su, Ning ^a,b   Peng, Liang ^a,b   Xia, Bingqing ^a,b   Zhao, Yingying ^a,b   Xu, Angao ^c   Wang, Jing ^a,b   Wang, Xinying ^a,b   Jiang, Bo ^a,b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Gastroenterology   (China)

^c Huizhou Medical Institute   (China)

Author keywords

CD24; Colorectal cancer; ERK1 2; Lyn

Indexed keywords

CD24 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE LYN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ATTENUATION; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; COLORECTAL CANCER; DISTANT METASTASIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN DEPLETION; PROTEIN PROTEIN INTERACTION;

ACTIVE TRANSPORT, CELL NUCLEUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; CELL LINE, TUMOR; CELL NUCLEUS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PROGNOSIS; PROTEIN BINDING; SRC-FAMILY KINASES; YOUNG ADULT;

EID: 84862668249     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-43     Document Type: Article

References (38)

1. Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004, 35:255-262.
2. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, Dietel M. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003, 9:4906-4913.
3. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58:183-192. 10.1002/pros.10324, 14716744.
4. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, Groth J, Coignet LJ, Gibbs JF. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 2007, 11:445-451. 10.1007/s11605-007-0091-5, 1852393, 17436128.
5. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH, Yuan RH. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007, 14:2748-2758. 10.1245/s10434-007-9501-x, 17680316.
6. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H, Arber N. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006, 131:630-639. 10.1053/j.gastro.2006.04.028, 16890615.
7. Wang W, Wang X, Peng L, Deng Q, Liang Y, Qing H, Jiang B. CD24-dependent MAPK pathway activation is required for colorectal cancer cell proliferation. Cancer Sci 2010, 101:112-119. 10.1111/j.1349-7006.2009.01370.x, 19860845.
8. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, Theodorescu D. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 2006, 66:1917-1922. 10.1158/0008-5472.CAN-05-3855, 16488989.
9. Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G, Altevogt P. CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis 2011,
10. Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res 2000, 60:6714-6722.
11. Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science 2009, 323:1722-1725. 10.1126/science.1168988, 2765686, 19264983.
12. Zarn JA, Zimmermann SM, Pass MK, Waibel R, Stahel RA. Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun 1996, 225:384-391. 10.1006/bbrc.1996.1184, 8753773.
13. Baumann P, Thiele W, Cremers N, Muppala S, Krachulec J, Diefenbacher M, Kassel O, Mudduluru G, Allgayer H, Frame M, Sleeman JP. CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion. Cell Mol Life Sci 2011,
14. Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R. The intracellular signal transduction mechanism of interleukin 5 in eosinophils: the involvement of lyn tyrosine kinase and the Ras-Raf-1-MEK-microtubule-associated protein kinase pathway. J Exp Med 1995, 181:1827-1834. 10.1084/jem.181.5.1827, 2192005, 7722458.
15. Bjorge JD, Jakymiw A, Fujita DJ. Selected glimpses into the activation and function of Src kinase. Oncogene 2000, 19:5620-5635. 10.1038/sj.onc.1203923, 11114743.
16. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004, 4:470-480. 10.1038/nrc1366, 15170449.
17. Janas ML, Hodgkin P, Hibbs M, Tarlinton D. Genetic evidence for Lyn as a negative regulator of IL-4 signaling. J Immunol 1999, 163:4192-4198.
18. Choi YL, Bocanegra M, Kwon MJ, Shin YK, Nam SJ, Yang JH, Kao J, Godwin AK, Pollack JR. LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. Cancer Res 2010, 70:2296-2306. 10.1158/0008-5472.CAN-09-3141, 2869247, 20215510.
19. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 2008, 68:3323-3333. 10.1158/0008-5472.CAN-07-2997, 18451159.
20. Montero JC, Seoane S, Ocana A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 2011, 17:5546-5552. 10.1158/1078-0432.CCR-10-2616, 21670084.
21. Hao JM, Chen JZ, Sui HM, Si-Ma XQ, Li GQ, Liu C, Li JL, Ding YQ, Li JM. A five-gene signature as a potential predictor of metastasis and survival in colorectal cancer. J Pathol 2010, 220:475-489.
22. Sammar M, Aigner S, Altevogt P. Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta 1997, 1337:287-294. 10.1016/S0167-4838(96)00177-X, 9048906.
23. Sammar M, Gulbins E, Hilbert K, Lang F, Altevogt P. Mouse CD24 as a signaling molecule for integrin-mediated cell binding: functional and physical association with src-kinases. Biochem Biophys Res Commun 1997, 234:330-334. 10.1006/bbrc.1997.6639, 9177270.
24. Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol 2001, 166:5567-5577.
25. Mierke CT, Bretz N, Altevogt P. Contractile Forces Contribute to Increased Glycosylphosphatidylinositol-anchored Receptor CD24-facilitated Cancer Cell Invasion. J Biol Chem 2011, 286:34858-34871. 10.1074/jbc.M111.245183, 21828044.
26. Hayakawa F, Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci 2006, 1086:213-222. 10.1196/annals.1377.002, 17185518.
27. Lee JH, Kim SH, Lee ES, Kim YS. CD24 overexpression in cancer development and progression: a meta-analysis. Oncol Rep 2009, 22:1149-1156.
28. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M, Kristiansen G. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005, 11:6574-6581. 10.1158/1078-0432.CCR-05-0606, 16166435.
29. Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D. CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 2011, 71:3802-3811. 10.1158/0008-5472.CAN-11-0519, 21482678.
30. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, Arber N. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008, 68:2803-2812. 10.1158/0008-5472.CAN-07-6463, 18413748.
31. Shapira S, Shapira A, Starr A, Kazanov D, Kraus S, Benhar I, Arber N. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology 2011, 140:935-946. 10.1053/j.gastro.2010.12.004, 21147107.
32. Ahmed MA, Al-Attar A, Kim J, Watson NF, Scholefield JH, Durrant LG, Ilyas M. CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer. J Clin Pathol 2009, 62:1117-1122. 10.1136/jcp.2009.069310, 19946098.
33. Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009, 15:2258-2264. 10.3748/wjg.15.2258, 2682242, 19437567.
34. Wang X, Li M, Wang J, Yeung CM, Zhang H, Kung HF, Jiang B, Lin MC. The BH3-only protein, PUMA, is involved in oxaliplatin-induced apoptosis in colon cancer cells. Biochem Pharmacol 2006, 71:1540-1550. 10.1016/j.bcp.2006.02.011, 16595125.
35. Yamaguchi N, Nakayama Y, Urakami T, Suzuki S, Nakamura T, Suda T, Oku N. Overexpression of the Csk homologous kinase (Chk tyrosine kinase) induces multinucleation: a possible role for chromosome-associated Chk in chromosome dynamics. J Cell Sci 2001, 114:1631-1641.
36. Lee EJ, Seo SR, Um JW, Park J, Oh Y, Chung KC. NF-kappaB-inducing kinase phosphorylates and blocks the degradation of Down syndrome candidate region 1. J Biol Chem 2008, 283:3392-3400.
37. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47:3239-3245.
38. Jin SH, Akiyama Y, Fukamachi H, Yanagihara K, Akashi T, Yuasa Y. IQGAP2 inactivation through aberrant promoter methylation and promotion of invasion in gastric cancer cells. Int J Cancer 2008, 122:1040-1046.